Novartis spent $15bn on M&A last year, with more to comeThe comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last Share XNovartis spent $15bn on M&A last year, with more to comehttps://pharmaphorum.com/news/novartis-spent-15bn-on-ma-last-year-with-more-to-come/
Jimenez to step down as Novartis chief, Narasimhan takes overJoe Jimenez is to step down after eight years as Novartis chief executive, and will be leaving on Share XJimenez to step down as Novartis chief, Narasimhan takes overhttps://pharmaphorum.com/news/jimenez-step-novartis-chief-narasimhan-takes/
AI helping us make smarter, faster decisions, says Novartis R&D chiefNovartis is trialling artificial intelligence (AI) in settings across drug discovery and drug development to help its scientists Share XAI helping us make smarter, faster decisions, says Novartis R&D chiefhttps://pharmaphorum.com/news/ai-helping-us-says-novartis-rd-chief/
